BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30239529)

  • 21. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
    Henry D; Taylor C
    Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Talking to patients about biosimilars.
    Janjigian YY; Bissig M; Curigliano G; Coppola J; Latymer M
    Future Oncol; 2018 Oct; 14(23):2403-2414. PubMed ID: 29856243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilars in oncology: key role of nurses in patient education.
    Waller CF; Friganović A
    Future Oncol; 2020 Sep; 16(25):1931-1939. PubMed ID: 32618476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical data and regulatory issues of biosimilar products.
    Stevenson JG
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
    Mellstedt H
    Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars: A Value Proposition.
    de Mora F
    BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are Biosimilars the Future of Oncology and Haematology?
    Zinzani PL; Dreyling M; Gradishar W; Andre M; Esteva FJ; Boulos S; González Barca E; Curigliano G
    Drugs; 2019 Oct; 79(15):1609-1624. PubMed ID: 31541401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars in oncology: everybody agrees but nobody uses?
    Gyawali B
    Recenti Prog Med; 2017 Apr; 108(4):172-174. PubMed ID: 28492585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars are coming: ready or not.
    Zalcberg J
    Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
    Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
    Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.